• Novoviah Novoleukin NovoGluten T-Cell Research Home Gluten

    NovoGluten Clinical Gluten

    Convenient, consistent and credible in gluten challenges throughout your program.

    Read More
  • Novoviah Novoleukin NovoGluten T-Cell Research Home Research

    Our Platform

    Novoviah develops customised ultrasensitive “Novoleukin” test kits to measure antigen-specific T cells during clinical trials.

    Read More
  • Novoviah Novoleukin NovoGluten T-Cell Research Home Laboratory

    Novoleukin System

    Our Novoleukin T-cell testing system detects T cells when others don’t. 

    Read More
  • Novoviah Novoleukin NovoGluten T-Cell Research Home Gluten

    Celiac Disease

    After 20+ years research, the first indication demonstrated for the Novoleukin Test System was is in Celiac Disease.

    Read More
  • Novoviah Novoleukin NovoGluten T-Cell Research Home Testing

    Future Applications

    Novoviah’s aspiration is to impact awide range of immune disease, therapies and vaccines.

    Read More

What we do ...

Novoviah works closely with your research and development team anywhere in the world to create a Novoleukin Test System customised to your needs and your antigens.

Novoviah Novoleukin NovoGluten T-Cell Research Home Icon 1

Our Platform

We make monitoring for antigen-specific T cells easy and sensitive for a clinical trial, by leveraging exceptional quality whole blood incubation with antigen at the trial site with standardised high-performance immunoassay at the central lab.

Read More
Novoviah Novoleukin NovoGluten T-Cell Research Home Icon 2

Novoleukin Test

The key, proprietary intellectual property is the Novoleukin test system, a “whole blood antigen-stimulated cytokine release assay” which is substantially more sensitive than conventional fresh PBMC-based ELISpot assay (e.g. for detection of gluten-reactive CD4+ T cells in celiac disease).

Read More
Novoviah Novoleukin NovoGluten T-Cell Research Home Icon 2

Celiac Disease

Novoviah has extensive experience of the Novoleukin Test System in Celiac Disease.  The Novoleukin-C test for gluten-specific T cells associated with celiac disease is reliable even in patients who have not completed a gluten food challenge. This is a landmark achievement in the field.

Read More
Novoviah Novoleukin NovoGluten T-Cell Research Home Icon 3

Other Applications

Novoviah’s aspiration is to have a Novoleukin Test System available for a wide range of antigens relevant to immune disease, therapies and vaccines, and to explore their clinical utility as diagnostics or monitoring tools. 

Read More

Why choose the Novoleukin test system? 

Novoviah Novoleukin NovoGluten T-Cell Research Home Icon 4
Precision

A “whole blood antigen-stimulated cytokine release assay” which is substantially more sensitive.

Novoviah Novoleukin NovoGluten T-Cell Research Home Icon 5
Simplicity

The protocol for blood collection and processing is simple and reproducible, to enable easy rollout across multiple sites.

Novoviah Novoleukin NovoGluten T-Cell Research Home Icon 5
CUSTOMISED

The Novoleukin Test System comprises three key elements: test kit and protocol, specific stimulation of cytokine release and central Lab Performing ultrasensitive cytokine assay.

Our Novoleukin T-cell testing system detects T cells when others don’t. Contact us today or click the button below to learn more and how our system may fit your appliation.
Read More Detail

NovoGluten for convenient, consistent and credible in gluten challenges throughout your program.

Standardized gluten powder for gluten challenges.

Building and understanding of dose response.

Same batch for your entire program from concept to approval.

75-80% pure gluten protein, low FODMAPs and pathogen free.

Prepackaged servings to be mixed with liquid in a NovoGluten shaker.

Extensive

charcterization.

Gluten food challenges must be tolerable and potent to inform clinical care and facilitate study endpoints. 
Read More Detail

NovoFind T-cell Epitome Mappping Platform

Revolutionary drug discovery platform for T cell mediated autoimmune diseases, infections, cancers and vaccine developments.

Development and design of an epitome mapping clinical trial.

Full CRO clinical trial services as required.

Leverage Novoviah's expertise in epitome mapping and clinical trials.

Customise your Novoleukin test.

Contact us today or click the button below to learn more and how our system may fit your appliation.
Contact Us

Our Executive Team & Founders

"Novoviah’s Founders are passionate about simple high performance T cell testing as diagnostic and monitoring tools accelerating pharmaceutical development, providing a new class of diagnostics, and allowing personalised treatment. 


Novoviah’s Novoleukin Test System has widespread application measuring rare antigen-specific T cells in autoimmunity, infectious diseases, cancer, vaccine and immunotherapy development, or as a powerful new clinical research tool. 


Novoviah has been built on our Founders’ over 20 years’ experience in discovery and commercialization of diagnostics and therapeutics for celiac disease and other immune diseases. Our Founders aim to bring simplicity and highest quality outcomes to support pharmas and biotech in preclinical and early clinical development of immunotherapy."


News & Articles

Explore the latest insights and advancements in T cell testing with Novoviah. Our blog, publications, and news articles offer a comprehensive look into our T cell testing platform for clinical trials and beyond. Stay informed with Novoviah's innovative solutions in biotechnology.

By Katie George July 24, 2022
Review article: Diagnosis of coeliac disease: a perspective on current and future approaches.  Summary Diagnostics will play a central role in addressing the ongoing dramatic rise in global prevalence of coeliac disease, and in deploying new non-dietary therapeutics. Clearer understanding of the immunopathogenesis of coeliac disease and the utility of serology has led to partial acceptance of non-biopsy diagnosis in selected cases. Non-biopsy diagnosis may expand further because research methods for measuring gluten-specific CD4+ T cells and the acute recall response to gluten ingestion in patients is now relatively straightforward. This perspective on diagnosis in the context of the immunopathogenesis of coeliac disease sets out to highlight current consensus, limitations of current practices, gluten food challenge for diagnosis and the potential for diagnostics that measure the underlying cause for coeliac disease, gluten-specific immunity.
By Katie George June 29, 2022
Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis. Abstract Introduction Recent patient studies have shown that gluten-free diet is less effective in treating celiac disease than previously believed, and additionally patients remain vulnerable to gluten-induced acute symptoms and systemic cytokine release. Safe and effective pharmacological adjuncts to gluten-free diet are in preclinical and clinical development. Clear understanding of the pathogenesis of celiac disease is critical for drug target identification, establishing efficacy endpoints and to develop noninvasive biomarkers suitable to monitor and potentially diagnose celiac disease. Areas covered The role and clinical effects of CD4+ T cells directed against deamidated gluten in the context of an ‘adaptive immune paradigm’ are reviewed. Alternative hypotheses of gluten toxicity are discussed and contrasted. In the context of recent patient studies, implications of the adaptive immune paradigm for future strategies to prevent, diagnose, and treat celiac disease are outlined. Expert Opinion Effective therapeutics for celiac disease are likely to be approved and necessitate a variety of new clinical instruments and tests to stratify patient need, monitor remission, and confirm diagnosis in uncertain cases. Sensitive assessments of CD4+ T cells specific for deamidated gluten are likely to play a central role in clinical management, and to facilitate research and pharmaceutical development. Click to read the full article ...
By Andor Rosenberg June 29, 2022
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease.  Abstract Progress has been made in understanding coeliac disease, a relatively frequent and underappreciated immune-mediated condition that occurs in genetically predisposed individuals. However, several gaps remain in knowledge related to diagnosis and management. The gluten-free diet, currently the only available management, is not curative or universally effective (some adherent patients have ongoing duodenal injury). Unprecedented numbers of emerging therapies, including some with novel tolerogenic mechanisms, are currently being investigated in clinical trials. In March 2020, the Celiac Disease Foundation and the Society for the Study of Celiac Disease convened a consensus workshop to identify high-yield areas of research that should be prioritized. Workshop participants included leading experts in clinical practice, academia, government and pharmaceutical development, as well as representatives from patient support groups in North America. This Roadmap summarizes key advances in the field of coeliac disease and provides information on important discussions from the consensus approach to address gaps and opportunities related to the pathogenesis, diagnosis and management of coeliac disease. The morbidity of coeliac disease is often underestimated, which has led to an unmet need to improve the management of these patients. Expanded research funding is needed as coeliac disease is a potentially curable disease. Click to read the full article ...
Share by: